Specificity is key to developing safe TCR or TCR-like antibody therapeutics. YUMAB’S novel CHO-display library presents the natural human pHLA repertoire on the cell surface, thereby enabling thorough counter-selections and screenings to identify TCRs or TCR-like antibodies with minimal off-target binding at early stages of drug discovery.
This case study explains how our new TCRm platform provides an innovative, solid foundation for the development of safe and effective therapeutics.
